iBio vs Kala Bio
IBIO and KALA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IBIO and KALA compare
iBio is the larger company, worth 18 times as much as Kala Bio ($47.1M against $2.7M).
iBio scores higher on the StockData Score (9 against 6 for Kala Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IBIO | KALA |
|---|---|---|
| Size and price | ||
| Market cap | $47.1M | $2.7M |
| Share price | $0.732 | $0.139 |
| Change, 1 year | −41.5% | −99.6% |
| Change, 5 years | −99.8% | −100.0% |
| Beta (5Y) | 1.12 | 0.34 |
| Employees | 23 | 6 |
| StockData Score | ||
| Total score | 9 (better) | 6 |
| Valuation score | 1 | 1 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 43.8× | – |
| P/B | 0.6× | 0.3× (better) |
| FCF yield | −58.6% | – |
| Growth | ||
| Revenue growth (TTM) | 115% | – |
| Revenue growth, 5Y average | −46.9% | – |
| Profitability | ||
| Operating margin | −3491% | – |
| Net margin | −3244% | – |
| FCF margin | −2566% | – |
| Return on equity | −51.8% (better) | −345% |
| Return on invested capital | −728% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 9.48 (better) | 6.88 |
| Altman Z-score | −3.49 (better) | −96.83 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 54.0% | 3.2% |
| Held by insiders | 0.47% | – |
| Insider net buying, 12 months | $98.1K (better) | $0 |
| Short interest, % of float | 6.3% | – |
Go deeper
- IBIO stock overview
- IBIO income statement
- IBIO valuation and score
- KALA stock overview
- KALA income statement
- KALA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.